The Dendreon Alumni: Where Are They Now?

Gilles Lefebvre, associate director, upstream process development, Trubion Pharmaceuticals

Therese Leggiere, quality assurance manager, Olympic Medical

Pocheng Liu, senior scientist, SAFC Pharma/Sigma Aldrich

Paul Lundy, senior director, facilities, Seattle Genetics [Added: 5 pm, 4/2/10]

Jerome Lyons, office manager, HemaQuest Pharmaceuticals

Ed Madison, chief scientific officer, Catalyst Biosciences

Kristi Manjarrez, senior director of clinical affairs, VentiRx Pharmaceuticals

Donna Matuizek, senior regulatory/quality assurance consultant/contractor, Harris Group

Cathy McMahan, associate director, cell sciences, Trubion Pharmaceuticals

Jenny Miller, biotech and medical device manufacturing training professional

Shirley Miller, software quality validation engineering consultant

Bryan Monroe, process science fellow, Life Technologies [Added: 8:15 pm, 4/1/10]

Gregg Monten, manager, quality control, Seattle Genetics

Ofir Moreno, managing director, Vivex International

Amy Myers, medical writing, PPD

Nancy Norton, senior commercial attorney, Avanade

Maria Ochoa, project manager, U.S. store services, Starbucks Coffee

Madhusudan Peshwa, executive vice president, cell therapies, MaxCyte

Grant Pickering, CEO, Juvaris BioTherapeutics

Abraham Polk, senior CMC project manager, Seattle Genetics

Aaron Posey, senior research associate, preclinical pharmacology, VLST [Updated: 2:10 pm, 3/31/10]

Julie Rathbun, owner, Rathbun Communications

Ellen Reimer, teacher, Seattle Public Schools

Rich Rieger, senior engagement manager, LEK Consulting [Updated: 11:15 pm, 3/31/10]

Israel Rios, chief medical officer, SciClone Pharmaceuticals

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.